• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Rise; Dow Gains 100 Points

    12/28/22 10:27:08 AM ET
    $COSM
    $GLYC
    $HUYA
    $KALA
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COSM alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.

    Following the market opening Wednesday, the Dow traded up 0.32% to 33,349.52 while the NASDAQ rose 0.45% to 10,400.04. The S&P 500 also rose, gaining, 0.40% to 3,844.62.

    Check This Out: Ethereum Slides Below $1,200; Terra Classic, Solana Among Top Losers


    Leading and Lagging Sectors


    Health care shares rose by 0.6% on Wednesday. Meanwhile, top gainers in the sector included GlycoMimetics, Inc. (NASDAQ:GLYC), up 12%, and Summit Therapeutics Inc. (NASDAQ:SMMT), up 10%.


    In trading on Wednesday, energy shares fell by 2%.


    Top Headline

     

    US pending home sales dropped 4% month-over-month in November, recording a sixth straight monthly drop.


    Equities Trading UP

     

    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shares shot up 117% to $8.49 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
    • Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) got a boost, shooting 15% to $2.5850.
    • Cosmos Health Inc. (NASDAQ:COSM) shares were also up, gaining 8% to $4.7723.

     

    Equities Trading DOWN

    • Minerva Neurosciences, Inc. (NASDAQ:NERV) shares tumbled 15% to $1.98. Minerva Neurosciences confirmed that the FDA's refuse letter from October 14, 2022 remains in effect.
    • Shares of HUYA Inc. (NYSE:HUYA) were down 14% to $3.7285.
    • Model Performance Acquisition Corp. (NASDAQ:MPAC) was down, falling 55% to $6.18.


    Also Check This Out: 5 Most Cheap IT Stocks You Should Think About


    Commodities

    In commodity news, oil traded down 0.5% to $79.17 while gold traded down 0.5% at $1,813.40.


    Silver traded down 0.8% to $24.025 on Wednesday while copper rose 0.1% to $3.8460.

     



    Euro zone


    European shares were mixed today. The eurozone’s STOXX 600 gained 0.3%, London’s FTSE 100 rose 0.8% while Spain’s IBEX 35 Index rose 0.2%. The German DAX fell 0.2%, French CAC 40 slipped 0.1% and Italy’s FTSE MIB Index fell 0.1%.

     


    Asia Pacific Markets


    Asian markets closed mixed on Wednesday, with the Japan’s Nikkei dropping 0.41%, Hong Kong’s Hang Seng Index gained 1.56% and China’s Shanghai Composite Index fell 0.26%.


    Industrial production in Japan declined by 0.1% month-over-month in November versus a 3.2% drop in October.

     

    Economics

     

    • US pending home sales dropped 4% month-over-month in November, recording a sixth straight monthly drop.
    • The Richmond Fed manufacturing index edged higher to 1 in December from -9 a month ago, while sector Activity revenues index declined to -12 in December from -2.

     

    Now Read This: Investor Fear Increases After Nasdaq Drops Over 1%


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 102,307,320 cases with around 1,116,360 deaths. India confirmed a total of at least 44,678,760 cases and 530,690 deaths, while France reported over 39,159,750 COVID-19 cases with 161,150 deaths. In total, there were at least 662,976,660 cases of COVID-19 worldwide with more than 6,689,300 deaths.

    Get the next $COSM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM
    $GLYC
    $HUYA
    $KALA

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    HUYA Inc.
    $HUYA
    11/5/2025$3.50Hold → Buy
    HSBC Securities
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    More analyst ratings

    $COSM
    $GLYC
    $HUYA
    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Purdy Brendan P.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:24 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Berger Chaim D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:15:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Posen Hillel D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:05 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    SEC Filings

    View All

    KALA BIO Inc. filed SEC Form 8-K: Leadership Update

    8-K - KALA BIO, Inc. (0001479419) (Filer)

    2/5/26 4:05:29 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc

    SCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/5/26 2:51:20 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)

    2/3/26 9:00:15 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies

    CHICAGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its digital assets program with the purchase of $500,000 of Bitcoin (BTC), underscoring the Company's disciplined, opportunistic, and flexible approach to capital deployment. The Company's digital assets program has so far been centered on Ethereum (ETH). While Ethereum will continue to serve as a key pillar of the program, the addition of Bitcoin represents a strategic evolution intended to broaden exposure across established digital assets. Cosmos Health is also selectively evaluati

    2/11/26 12:10:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Huya Announces Return of E-sports Icon Uzi, Underscoring Huya's Growing Appeal to Top Streamers

    GUANGZHOU, China, Feb. 2, 2026 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE:HUYA), a leading game-related entertainment and services provider, today announced that Jian "Uzi" Zihao, a former top-tier professional League of Legends player widely recognized for his competitive achievements in the global e-sports industry, will return to the Huya platform commencing with a special live stream scheduled for February 3. Uzi's return underscores Huya's growing appeal as a preferred destination for top-tier e-sports talent. Huya has consistently demonstrated its ability to attract and support leading and rising streamers, fostering an environment that nurtures long-term engagement bet

    2/2/26 9:15:00 AM ET
    $HUYA
    Computer Software: Programming Data Processing
    Technology

    $COSM
    $GLYC
    $HUYA
    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $175,000 worth of shares (353,321 units at $0.50), increasing direct ownership by 5% to 8,091,795 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/21/26 10:11:57 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/15/26 9:40:58 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUYA upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded HUYA from Hold to Buy and set a new price target of $3.50

    11/5/25 7:23:39 AM ET
    $HUYA
    Computer Software: Programming Data Processing
    Technology

    $COSM
    $GLYC
    $HUYA
    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GlycoMimetics Inc.

    SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HUYA Inc.

    SC 13G/A - HUYA Inc. (0001728190) (Subject)

    11/14/24 7:57:41 PM ET
    $HUYA
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    Financials

    Live finance-specific insights

    View All

    HUYA Inc. to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

    -Earnings Webinar Scheduled for 5:00 a.m. ET on November 12, 2025- GUANGZHOU, China, Oct. 22, 2025 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE:HUYA), a leading game-related entertainment and services provider, today announced that it will report its third quarter 2025 unaudited financial results on Wednesday, November 12, 2025, before the open of U.S. markets. The Company's management will host a Tencent Meeting Webinar at 5:00 a.m. U.S. Eastern Time on November 12, 2025 (6:00 p.m. Beijing/Hong Kong time on November 12, 2025), to review and discuss the Company's business and financial performance. For participants who wish to join the webinar, please complete the online regist

    10/22/25 6:00:00 AM ET
    $HUYA
    Computer Software: Programming Data Processing
    Technology

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

    Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared

    10/20/25 6:45:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60 Tolerable Safety Profile Reaffirmed for PD-1 / VEGF Bispecific in Squamous NSCLC: Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation & Death Rates Were Observed in the Two Arms of HARMONi-6 Summit-Sponsored HARMONi-3 Global Study Will be Split into Two Analyses by Histology: Squamo

    10/19/25 10:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COSM
    $GLYC
    $HUYA
    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Appoints David Lubner to Board of Directors

    Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

    4/28/25 7:30:00 AM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care